NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $1.62 +0.13 (+8.72%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.96 +0.35 (+21.30%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Esperion Therapeutics Stock (NASDAQ:ESPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Esperion Therapeutics alerts:Sign Up Key Stats Today's Range$1.59▼$1.7250-Day Range$0.83▼$1.6252-Week Range$0.69▼$3.94Volume8.20 million shsAverage Volume5.16 million shsMarket Capitalization$321.08 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Read More Esperion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreESPR MarketRank™: Esperion Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 352nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEsperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.35% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.76 Percentage of Shares Shorted11.35% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.33 News SentimentEsperion Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.Search Interest12 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,184.00 in company stock.Percentage Held by InsidersOnly 1.70% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesEsperion (ESPR) Q2 Revenue Jumps 12%5 hours ago | fool.comEsperion rises after revenue beat, Q1 profitability expectationAugust 5 at 12:15 PM | seekingalpha.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Esperion Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 5 at 6:00 AM | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.00 Average PT from AnalystsAugust 3 at 2:33 AM | americanbankingnews.comZacks Research Analysts Increase Earnings Estimates for ESPRAugust 1, 2025 | americanbankingnews.comCritical Analysis: Esperion Therapeutics (NASDAQ:ESPR) and Korro Bio (NASDAQ:KRRO)July 29, 2025 | americanbankingnews.comEsperion Therapeutics soars amid vague takeover speculationJuly 24, 2025 | msn.comSee More Headlines ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $2.20 at the start of the year. Since then, ESPR stock has decreased by 26.4% and is now trading at $1.62. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday, August, 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The biopharmaceutical company had revenue of $82.39 million for the quarter, compared to the consensus estimate of $62.55 million. Esperion Therapeutics had a negative trailing twelve-month return on equity of 0.91% and a negative net margin of 59.03%. Read the conference call transcript. Who are Esperion Therapeutics' major shareholders? Top institutional shareholders of Esperion Therapeutics include UMB Bank n.a. (0.09%), Parallel Advisors LLC (0.06%), Boomfish Wealth Group LLC (0.02%) and Sivia Capital Partners LLC (0.01%). Insiders that own company stock include Benjamin Halladay, Benjamin Looker, Sheldon L Koenig, Eric Warren, Joanne M Foody and J Martin Carroll. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AU Optronics (AUOTY). Company Calendar Today8/05/2025Last Earnings8/05/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Esperion Therapeutics$7.00 High Price Target$16.00 Low Price Target$3.00 Potential Upside/Downside+332.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.74 million Net Margins-59.03% Pretax Margin-59.03% Return on Equity-0.91% Return on Assets-29.47% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio0.81 Sales & Book Value Annual Sales$332.31 million Price / Sales0.97 Cash Flow$0.03 per share Price / Cash Flow62.02 Book Value($1.97) per share Price / Book-0.82Miscellaneous Outstanding Shares198,200,000Free Float194,830,000Market Cap$321.08 million OptionableOptionable Beta0.82 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ESPR) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.